{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:53:09Z","timestamp":1792756389152,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Several HCV patients in Brazil were lost to follow-up (LTFU) in the last two decades before achievement of sustained virological response (SVR). Strategies to recall those diagnosed but untreated patients have been used elsewhere with different success rates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To identify and retrieve LTFU patients in order to offer them the treatment with the current highly effective direct acting antiviral agents (DAAs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Registries ofall HCV patients from three large reference centers in Brazil were retrospectively reviewed to identify those with no registry of SVR. Reasons for non-achievement of SVR were elicited in HCV-RNA\u2009+\u2009patients. All patients who were not treated or cured were contacted to offer the therapy with DAAs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>10,289 HCV patients (50% males, mean age 52\u2009\u00b1\u200911 years) were identified. Only 4,293 (41.7%) had been successfully treated previously. From the remaining 5,996 most were LTFU (59%), were not treated for other reasons (14.7%) or were non-responders (26.3%). After revision of the charts 3,559 were considered eligible to be retrieved. The callback success of phone calls was 18%, 13% to cellphone messages (SMS or WhatsApp) and 7% to regular mail. Five-hundred sixty patients had been already treatedor were on treatment and 234 were reported to be dead or transplanted. Finally, 201 had made an appointment and initiated antiviral treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Even considering the low callback rate, retrieval of LTFU patients was shown to be an important strategy forhepatitis C micro-elimination in Brazil.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12879-023-08169-0","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T08:03:17Z","timestamp":1689235397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Retrieval of HCV patients lost to follow-up as a strategy for Hepatitis C Microelimination: results of a Brazilian multicentre study"],"prefix":"10.1186","volume":"23","author":[{"given":"Maria Lucia Gomes","family":"Ferraz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Ricardo Cardia Ferraz","family":"de Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Henrique Santos","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana","family":"Codes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Lisboa","family":"Bittencourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"key":"8169_CR1","doi-asserted-by":"crossref","unstructured":"Polaris Observatory HCV, Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet GastroenterolHepatol. 2022;7:396\u2013415.","DOI":"10.1016\/S2468-1253(21)00472-6"},{"key":"8169_CR2","unstructured":"World Health Organization. Hepatitis C key facts. July 2021. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c Accessed in 24 Feb 2022."},{"key":"8169_CR3","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1080\/14656566.2021.1921737","volume":"22","author":"C Stanciu","year":"2021","unstructured":"Stanciu C, Muzica CM, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, et al. An update on direct antiviral agents for the treatment of hepatitis C. Expert OpinPharmacother. 2021;22:1729\u201341.","journal-title":"Expert OpinPharmacother"},{"issue":"6","key":"8169_CR4","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.aohep.2019.08.001","volume":"18","author":"CM de Oliveira Lobato","year":"2019","unstructured":"de Oliveira Lobato CM, Codes L, Silva GF, SouzaAFM CoelhoHSM, Pedroso ML, et al. Direct antiviral therapy for treatment of hepatitis C: a real-world study from Brazil. Ann Hepatol. 2019;18(6):849\u201354.","journal-title":"Ann Hepatol"},{"issue":"4","key":"8169_CR5","doi-asserted-by":"publisher","first-page":"102388","DOI":"10.1016\/j.bjid.2022.102388","volume":"26","author":"MLG Ferraz","year":"2022","unstructured":"Ferraz MLG, de Zorzi Piccoli L, Rezende R, BorbaL A, Junior AP, Cheinquer H, et al. National brazilian survey on the outcomes of hepatitis C retreatment in patients non-responders to direct antiviral agents. Brazilian J Infect Dis. 2022;26(4):102388.","journal-title":"Brazilian J Infect Dis"},{"key":"8169_CR6","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis, 2016\u20132021: towards ending viral hepatitis. 2016. Available from http:\/\/apps.who.int\/iris\/bitstream\/10665\/246177\/1\/WHO-HIV-2016.06-eng.pdf."},{"issue":"2","key":"8169_CR7","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jhep.2021.08.005","volume":"76","author":"RF do Carmo","year":"2022","unstructured":"do Carmo RF, de Souza CDF. Impact of the COVID-19 pandemic on hepatitis C diagnosis in Brazil: is the global hepatitis C elimination strategy at risk? J Hepatol. 2022;76(2):470.","journal-title":"J Hepatol"},{"issue":"1","key":"8169_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jhep.2020.07.042","volume":"74","author":"S Blach","year":"2021","unstructured":"Blach S, Kondili LA, Aghemo A, Cai Z, Dugan E, Estes C, et al. Impact of COVID-19 on global HCV elimination efforts. J Hepatol. 2021;74(1):31\u20136.","journal-title":"J Hepatol"},{"key":"8169_CR9","unstructured":"Polaris Observatory HCV. Collaborators.Year of Achieving Elimination Targets (Extrapolated from 2020 Data) Current WHO Target is 2030. https:\/\/cdafound.org\/polaris-countries-dashboard\/. Accessed in Oct 20, 2022."},{"issue":"1","key":"8169_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12876-021-01792-8","volume":"21","author":"HH Yen","year":"2021","unstructured":"Yen HH, Su PY, Liu IL, Zeng YH, Huang SP, Hsu YC, Hsu PK, Chen YY. Retrieval of lost patients in the system for hepatitis C microelimination: a single-center retrospective study. BMC Gastroenterol. 2021;21(1):1\u20137.","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"8169_CR11","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/liv.13959","volume":"39","author":"PAM Kracht","year":"2019","unstructured":"Kracht PAM, Arends JE, van Erpecum KJ, Thijsen SFT, Vlaminckx BJM, Weersink AJL, et al. Retrieval and cure of chronic hepatitis C (REACH): results of micro-elimination in the Utrecht province. Liver Int. 2019;39(3):455\u201362.","journal-title":"Liver Int"},{"issue":"1","key":"8169_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41124-018-0032-9","volume":"3","author":"N Beekmans","year":"2018","unstructured":"Beekmans N, Klemt-Kropp M. Re-evaluation of chronic hepatitis B and hepatitis C patients lost to follow-up: results of the northern Holland hepatitis retrieval project. Hepatol Med Policy. 2018;3(1):1\u20136.","journal-title":"Hepatol Med Policy"},{"key":"8169_CR13","unstructured":"Ministry of Health, Brazil. Clinical protocols and therapeutic guidelines \u2013 PCDT for hepatitis C and coinfections.http:\/\/www.aids.gov.br\/pt-br\/pub\/2019\/protocolo-clinico-e-diretrizes-terapeuticas-para-hepatite-c-e-coinfeccoes. (Accessed on 2 Oct 2022)."},{"issue":"5 Suppl 1","key":"8169_CR14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1053\/jhep.2002.36810","volume":"36","author":"MW Fried","year":"2002","unstructured":"Fried MW. Side effects of thepapy of hepatitis C and their management. Hepatology. 2002;36(5 Suppl 1):237\u201344.","journal-title":"Hepatology"},{"key":"8169_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ebiom.2016.08.035","volume":"12","author":"NZ Janjua","year":"2016","unstructured":"Janjua NZ, Kuo M, Yu A, Alvarez M, Wong S, Cook D, et al. The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: the BC Hepatitis Testers Cohort (BC-HTC). EBioMedicine. 2016;12:189\u201395.","journal-title":"EBioMedicine"},{"issue":"Suppl 2","key":"8169_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/00333549161310S209","volume":"131","author":"AG Geboy","year":"2016","unstructured":"Geboy AG, Mahajan S, Daly AP, Sewell CF, Fleming IC, Cha HA, et al. High Hepatitis C infection rate among Baby Boomers in an Urban Primary Care Clinic: results from the HepTLC. Initiative Publ Health Report. 2016;131(Suppl 2):49\u201356.","journal-title":"Initiative Publ Health Report"},{"key":"8169_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejim.2022.04.024","volume":"101","author":"CJ Isfordink","year":"2022","unstructured":"Isfordink CJ, van Dijk M, Brakenhoff SM, Kracht PA, Arends JE, de Knegt RJ, et al. Hepatitis C elimination in the Netherlands (CELINE): how nationwide retrieval of lost to follow-up hepatitis C patients contributes to micro-elimination. Eur J Intern Med. 2022;101:93\u20137.","journal-title":"Eur J Intern Med"},{"issue":"7","key":"8169_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/jvh.13686","volume":"29","author":"E Vargas-Accarino","year":"2022","unstructured":"Vargas-Accarino E, Mart\u00ednez\u2010Campreci\u00f3s J, Dom\u00ednguez\u2010Hern\u00e1ndez R, Rando\u2010Segura A, Riveiro\u2010Barciela M, Rodr\u00edguez\u2010Fr\u00edas F, et al. Cost\u2010effectiveness analysis of an active search to retrieve HCV patients lost to follow\u2010up (RELINK\u2010C strategy) and the impact of COVID\u201019. J Viral Hepat. 2022;29(7):579\u201383.","journal-title":"J Viral Hepat"},{"key":"8169_CR19","doi-asserted-by":"publisher","unstructured":"Mendizabal M, Thompson M, Gonzalez-Ballerga E, Anders M, Castro-Narro GE, Pessoa MG et al. Implementation of a re-linkage to care strategy in patients with chronic hepatitis c who were lost to follow-up in Latin America. J Viral Hepat2022 Oct 5.doi: https:\/\/doi.org\/10.1111\/jvh.13758. Online ahead of print.","DOI":"10.1111\/jvh.13758"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08169-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08169-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08169-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T02:09:51Z","timestamp":1729735791000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08169-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,13]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8169"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08169-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,13]]},"assertion":[{"value":"29 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Ethical Committee from Federal University of Sao Paulo (number5.168.251). All methods were performed in accordance with the DECLARATION OF HELSINKI guidelines for reporting observational studies. All patients provided informed consent to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"468"}}